Gut bacteria boost may resensitize kidney tumors to immunotherapy

NCT ID NCT07611825

Recruiting now Disease control Sponsor: Jinling Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 4 times

Summary

This study tests whether altering gut bacteria can restore the effectiveness of immunotherapy in people with advanced kidney cancer. About 33 adults will receive a bowel cleanse, a live bacterial supplement, and then a combination of immunotherapy drugs. The goal is to see if this approach can shrink tumors or slow cancer growth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED RCC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED RCC

Contacts and locations

Locations

Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University
NOT_YET_RECRUITING

Nanjing, Jiangsu, 210000, China
Jinling Hospital,Affiliated Hospital of Medical School,Nanjing University
RECRUITING

Nanjing, Jiangsu, 210002, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.